skip to content
Detailed Quote
Questions on this company?
Become a Member
Company Profile
{tplLang.businessdescription | toLang tLang}
{ profileData.description }

{tplLang.details | toLang tLang}

{tplLang.ceo | toLang tLang}
{profileData.profile.details.ceo}
{tplLang.employees | toLang tLang}
{profileData.profile.details.employees | numeraljs '0,0'}
{tplLang.issuetype | toLang tLang}
{profileData.profile.details.issuetype | asIssueType}

{tplLang.industryclassifications | toLang tLang}

{tplLang.sector | toLang tLang}
{profileData.profile.classification.sector}
{tplLang.industry | toLang tLang}
{profileData.profile.classification.industry}

{tplLang.toolname| toLang tLang}

There is no {tplLang.toolname| toLang tLang} currently available for {data.symbolstring}.
Interactive Chart
Key Ratios
Earnings
Analyst Recommendations
5i Recent Questions
Q: Hi

Your recent answer to Steven on December 08 2020 appears to favor EDGE. (Not able to pull this symbol on your database yet. Comes up as Edge therapeutics)
I also know that ARKK is one of your favorites through your answers to others' questions.
Now that AUM is going up with EDGE, and their lower fees (50% less than ARKK) would you say EDGE for a 2% initial position and for adding a little bit more if there is a correction is reasonable?
I am bit surprised that a Canadian ETF company offers an all in ETF for a lower fees compared to its US counterparts. How do they do it?!!
Read Answer Asked by Savalai on December 15, 2020
Insiders
Share Information
SEC Filings
News and Media